Discontinued — last reported Q4 '24
Humalog® — Revenue
Eli Lilly Humalog® — Revenue increased by 16.0% to $619.90M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 69.0%, from $366.70M to $619.90M. Over 3 years (FY 2021 to FY 2024), Humalog® — Revenue shows relatively stable performance with a -1.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase suggests stable demand or successful lifecycle management, while a decrease often signals market share erosion due to biosimilar entry or a strategic shift in patient treatment toward newer therapeutic classes.
Detailed definition
This metric represents the total global net sales generated from the Humalog product line, which is a rapid-acting insul...
Peer comparison
Comparable to revenue metrics for mature, off-patent, or legacy pharmaceutical products at peers like Novo Nordisk or Sanofi, where volume and pricing are pressured by generic or biosimilar alternatives.
lly_segment_humalog_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $607.60M | $626.70M | $601.70M | $618.20M | $447.10M | $447.00M | $548.30M | $460.90M | $440.40M | $395.40M | $366.70M | $538.70M | $631.60M | $534.60M | $619.90M |
| QoQ Change | — | +3.1% | -4.0% | +2.7% | -27.7% | -0.0% | +22.7% | -15.9% | -4.4% | -10.2% | -7.3% | +46.9% | +17.2% | -15.4% | +16.0% |
| YoY Change | — | — | — | — | -26.4% | -28.7% | -8.9% | -25.4% | -1.5% | -11.5% | -33.1% | +16.9% | +43.4% | +35.2% | +69.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's humalog® — revenue?
- Eli Lilly (LLY) reported humalog® — revenue of $619.90M in Q4 2024.
- How has Eli Lilly's humalog® — revenue changed year-over-year?
- Eli Lilly's humalog® — revenue increased by 69.0% year-over-year, from $366.70M to $619.90M.
- What is the long-term trend for Eli Lilly's humalog® — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's humalog® — revenue has grown at a -1.8% compound annual growth rate (CAGR), from $2.45B to $2.32B.
- What does humalog® — revenue mean?
- The total revenue generated from sales of the Humalog insulin product line.